New pill tested for Tough-to-Treat blood disorder
NCT ID NCT07006025
Summary
This early-stage study is testing a new oral drug combination (THU and decitabine) for adults with myelodysplastic syndromes (MDS) that have returned or not responded to prior treatment. The main goals are to check the safety of the drugs and see if they improve health and reduce hospital stays. Participants will take the pills once a week for 24 weeks and visit the clinic monthly for checkups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Einstein Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.